Table 1. Patient characteristics, according to receipt of chemotherapy, Stage I-III breast cancer patients, Kaiser Permanente Northern California, 2004-2007.
Received chemotherapyb | Total | |||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Yes | No | |||||||
|
|
|||||||
N | Column (%) | Row (%) | N | Column (%) | Row (%) | N | Column (%) | |
Age at diagnosis (years)a | ||||||||
0–39 | 213 | 8.0 | 86.9 | 32 | 1.0 | 13.1 | 245 | 4.1 |
40–49 | 763 | 28.6 | 74.4 | 263 | 7.9 | 25.6 | 1026 | 17.1 |
50–59 | 927 | 34.7 | 55.6 | 739 | 22.2 | 44.4 | 1666 | 27.7 |
60–69 | 556 | 20.8 | 36.8 | 955 | 28.6 | 63.2 | 1511 | 25.2 |
≥70 | 210 | 7.9 | 13.5 | 1346 | 40.4 | 86.5 | 1556 | 25.9 |
Race/Ethnicitya | ||||||||
Non–Hispanic (NH) White | 1670 | 62.6 | 40.8 | 2428 | 72.8 | 59.2 | 4098 | 68.3 |
NH Black | 228 | 8.5 | 53.0 | 202 | 6.1 | 47.0 | 430 | 7.2 |
Hispanic | 345 | 12.9 | 54.2 | 291 | 8.7 | 45.8 | 636 | 10.6 |
NH Asian/Pacific Islander | 400 | 15.0 | 51.9 | 370 | 11.1 | 48.1 | 770 | 12.8 |
NH American Indian/Alaskan Native, other, or unknown | 26 | 1.0 | 37.1 | 44 | 1.3 | 62.9 | 70 | 1.2 |
Socio-economic status, quintilesa | ||||||||
Lowest quintile | 122 | 4.6 | 43.3 | 160 | 4.8 | 56.7 | 282 | 4.7 |
Second quintile | 325 | 12.2 | 44.9 | 399 | 12.0 | 55.1 | 724 | 12.1 |
Third quintile | 499 | 18.7 | 43.5 | 647 | 19.4 | 56.5 | 1146 | 19.1 |
Fourth quintile | 780 | 29.2 | 44.4 | 977 | 29.3 | 55.6 | 1757 | 29.3 |
Highest quintile | 943 | 35.3 | 45.0 | 1152 | 34.5 | 55.0 | 2095 | 34.9 |
Marital statusa | ||||||||
Single, separated, divorced, widowed | 903 | 33.8 | 37.6 | 1501 | 45.0 | 62.4 | 2404 | 40.0 |
Married | 1745 | 65.4 | 49.2 | 1804 | 54.1 | 50.8 | 3549 | 59.1 |
Unknown | 21 | 0.8 | 41.2 | 30 | 0.9 | 58.8 | 51 | 0.8 |
Tumor Size (cm)a | ||||||||
<1 | 156 | 5.8 | 13.1 | 1034 | 31.0 | 86.9 | 1190 | 19.8 |
1 to <2 | 888 | 33.3 | 38.6 | 1415 | 42.4 | 61.4 | 2303 | 38.4 |
2 to <3 | 810 | 30.3 | 61.3 | 512 | 15.4 | 38.7 | 1322 | 22.0 |
3 to <4 | 391 | 14.6 | 71.0 | 160 | 4.8 | 29.0 | 551 | 9.2 |
4 to <5 | 219 | 8.2 | 77.9 | 62 | 1.9 | 22.1 | 281 | 4.7 |
≥5 | 165 | 6.2 | 74.7 | 56 | 1.7 | 25.3 | 221 | 3.7 |
Microscopic foci, diffuse, or not stated | 40 | 1.5 | 29.4 | 96 | 2.9 | 70.6 | 136 | 2.3 |
Lymph node involvementa | ||||||||
No nodes | 1202 | 45.0 | 29.1 | 2935 | 88.0 | 70.9 | 4137 | 68.9 |
Positive nodes | 1464 | 54.9 | 78.7 | 397 | 11.9 | 21.3 | 1861 | 31.0 |
Unknown | 3 | 0.1 | 50.0 | 3 | 0.1 | 50.0 | 6 | 0.1 |
Stagea | ||||||||
Stage I | 667 | 25.0 | 21.1 | 2501 | 75.0 | 78.9 | 3168 | 52.8 |
Stage II | 1451 | 54.4 | 66.5 | 732 | 21.9 | 33.5 | 2183 | 36.4 |
Stage III | 551 | 20.6 | 84.4 | 102 | 3.1 | 15.6 | 653 | 10.9 |
Gradea | ||||||||
Grade I (well differentiated) | 267 | 10.0 | 19.8 | 1081 | 32.4 | 80.2 | 1348 | 22.5 |
Grade II (moderately well differentiated) | 1028 | 38.5 | 42.0 | 1419 | 42.5 | 58.0 | 2447 | 40.8 |
Grade III (poorly or undifferentiated) | 1219 | 45.7 | 69.4 | 537 | 16.1 | 30.6 | 1756 | 29.2 |
Grade and differentiation not stated | 155 | 5.8 | 34.2 | 298 | 8.9 | 65.8 | 453 | 7.5 |
Histologya | ||||||||
Ductal | 2002 | 75.0 | 46.0 | 2347 | 70.4 | 54.0 | 4349 | 72.4 |
Lobular | 510 | 19.1 | 42.0 | 703 | 21.1 | 58.0 | 1213 | 20.2 |
Both | 157 | 5.9 | 35.5 | 285 | 8.5 | 64.5 | 442 | 7.4 |
Estrogen and progesterone receptorsa | ||||||||
Positive (either or both) | 1878 | 70.4 | 38.5 | 2997 | 89.9 | 61.5 | 4875 | 81.2 |
Negative (both) | 778 | 29.1 | 71.6 | 309 | 9.3 | 28.4 | 1087 | 18.1 |
Unknown (both) | 13 | 0.5 | 31.0 | 29 | 0.9 | 69.0 | 42 | 0.7 |
HER2/Neu (HER2)a | ||||||||
Positive | 482 | 18.1 | 71.3 | 194 | 5.8 | 28.7 | 676 | 11.3 |
Negative | 1539 | 57.7 | 39.3 | 2381 | 71.4 | 60.7 | 3920 | 65.3 |
Unknown or borderline | 648 | 24.3 | 46.0 | 760 | 22.8 | 54.0 | 1408 | 23.5 |
Charlson Comorbidity Indexb | ||||||||
0 | 2232 | 83.6 | 48.2 | 2403 | 72.1 | 51.8 | 4635 | 77.2 |
1 | 338 | 12.7 | 35.7 | 608 | 18.2 | 64.3 | 946 | 15.8 |
2 | 72 | 2.7 | 28.0 | 185 | 5.5 | 72.0 | 257 | 4.3 |
≥3 | 27 | 1.0 | 16.3 | 139 | 4.2 | 83.7 | 166 | 2.8 |
Diabetesb | ||||||||
Yes | 205 | 7.7 | 30.1 | 475 | 14.2 | 69.9 | 680 | 11.3 |
No | 2464 | 92.3 | 46.3 | 2860 | 85.8 | 53.7 | 5324 | 88.7 |
Neuropathyb | ||||||||
Yes | 44 | 1.6 | 23.5 | 143 | 4.3 | 76.5 | 187 | 3.1 |
No | 2625 | 98.4 | 45.1 | 3192 | 95.7 | 54.9 | 5817 | 96.9 |
Heart Diseaseb | ||||||||
Yes | 82 | 3.1 | 18.9 | 353 | 10.6 | 81.1 | 435 | 7.2 |
No | 2587 | 96.9 | 46.5 | 2982 | 89.4 | 53.5 | 5569 | 92.8 |
Modified Charlson Comorbidity Indexc | ||||||||
0 | 2403 | 90.0 | 46.1 | 2813 | 84.3 | 53.9 | 5216 | 86.9 |
1 | 239 | 9.0 | 36.5 | 416 | 12.5 | 63.5 | 655 | 10.9 |
2 | 24 | 0.9 | 24.7 | 73 | 2.2 | 75.3 | 97 | 1.6 |
≥3 | 3 | 0.1 | 8.3 | 33 | 1.0 | 91.7 | 36 | 0.6 |
Multiple primary tumors diagnosed within 60 daysa | ||||||||
Yes | 44 | 1.6 | 44.9 | 54 | 1.6 | 55.1 | 98 | 1.6 |
No | 2625 | 98.4 | 44.4 | 3281 | 98.4 | 55.6 | 5906 | 98.4 |
Endocrine therapyb, d | ||||||||
Yes | 1750 | 93.2 | 42.0 | 2419 | 80.7 | 58.0 | 4169 | 85.5 |
No | 128 | 6.8 | 18.1 | 578 | 19.3 | 81.9 | 706 | 14.5 |
Radiation therapya | ||||||||
Yes | 1137 | 42.6 | 37.6 | 1887 | 56.6 | 62.4 | 3024 | 50.4 |
No | 1532 | 57.4 | 51.4 | 1448 | 43.4 | 48.6 | 2980 | 49.6 |
Surgerya | ||||||||
Mastectomy | 1326 | 49.7 | 56.8 | 1008 | 30.2 | 43.2 | 2334 | 38.9 |
Breast conserving surgery | 1300 | 48.7 | 36.4 | 2271 | 68.1 | 63.6 | 3571 | 59.5 |
Other or no surgery | 43 | 1.6 | 43.4 | 56 | 1.7 | 56.6 | 99 | 1.6 |
Anthracycline (doxorubixcin, epirubicin)e | ||||||||
Yes | 2477 | 92.8 | 100.0 | 2477 | 41.3 | |||
No | 192 | 7.2 | 5.4 | 3335 | 100.0 | 94.6 | 3527 | 58.7 |
Taxane (docetaxel, paclitaxel)e | ||||||||
Yes | 1659 | 62.2 | 100.0 | 1659 | 27.6 | |||
No | 1010 | 37.8 | 23.2 | 3335 | 100.0 | 76.8 | 4345 | 72.4 |
Trastuzumabe | ||||||||
Yes | 491 | 18.4 | 100.0 | 491 | 8.2 | |||
No | 2178 | 81.6 | 39.5 | 3335 | 100.0 | 60.5 | 5513 | 91.8 |
Combination chemotherapy within 4 months, among women with ER/PR-negative tumors ≥1 cm in size and age <70 yearsf | ||||||||
Yes | 595 | 92.5 | 100.0 | 595 | 81.3 | |||
No | 48 | 7.5 | 35.0 | 89 | 100.0 | 65.0 | 137 | 18.7 |
Trastuzumab, among women diagnosed in 2006–2007 with HER2-positive tumorsf | ||||||||
Yes | 199 | 88.8 | 100.0 | 199 | 68.4 | |||
No | 25 | 11.2 | 27.2 | 67 | 100.0 | 72.8 | 92 | 31.6 |
Total | 2669 | 100.0 | 44.5 | 3335 | 100.0 | 55.5 | 6004 | 100.0 |
Data from the California Cancer Registry
Data from Kaiser Permanente Northern California
This modified Charlson Comorbidity Index excluded heart disease, diabetes and neuropathy, which were evaluated separately
Limited to women with estrogen receptor and/or progesterone receptor-positive breast cancers (N = 4875)
Among women who received chemotherapy
Measure of the American Society of Clinical Oncology Quality Oncology Practice Initiative (ASCO QOPI)